Volume 25, Issue 1 (2022)                   mjms 2022, 25(1): 61-67 | Back to browse issues page

Ethics code: IR. MODARES.REC.1396.4321

XML Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Ehghaghi E, Ravanshad M. Investigation the effect of Silymarin on cyclooxygenase-2 (COX-2) gene expression in HCV infected cell line. mjms 2022; 25 (1) :61-67
URL: http://mjms.modares.ac.ir/article-30-65479-en.html
1- Department of Virology, Faculty of Medical Sciences, Tarbiat Modares University
2- Department of Virology, Faculty of Medical Sciences, Tarbiat Modares University , ravanshad@modares.ac.ir
Abstract:   (349 Views)
Hepatitis C infection causes an increase in oxidative stress in infected cells, followed by Cyclooxygenase-2 (COX-2) gene expression. Silybum marianum, is one of the most widely used medicinal plants that has been used to control and reduce hepatitis manifestations, which contains silymarin –the effective component- that could protect liver cells.
In this study, Huh7 cell line originated from liver were infected by HCV virus model and then treated by silymarin. In order to investigate the anti-oxidative effect, the expression of COX-2 gene that plays central role, was measured in serial concentration of silymarin by developed quantitative RT-Real time-PCR.
Findings of the study showed that silymarin could control expression of COX-2 as well as oxidative stress. It was showed that, silymarin at the concentration of more than 200μM could reduce the expression of COX-2 and oxidative stress, and also it was concluded that silymarin above 300μM, could likewise have therapeutic effect on increased oxidative stress as well as COX-2 gene expression in HCV infected cells.
Conclusion It was concluded that inhibition of COX-2 by silymarin has been considered as a promising and effective strategy for prevention and treatment of HCV and liver injuries and cancer.

Keywords: COX-2, HCV, Silymarin
Full-Text [PDF 392 kb]   (47 Downloads)    
Article Type: Original Research | Subject: Molecular Medicine
Received: 2022/11/16 | Accepted: 2023/01/18

Send email to the article author

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.